



Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?

Published: 2010-MAR-01

Pages: 1289

Format: PDF

Price: 2450 EUR (Single User License)

Description

The antibody market represents the fastest-growing segment within the pharmaceutical industry. As such it has become a complex and crowded market place. This is particularly true for the cancer market. When navigating in the competitive landscape of antibody therapeutics in oncology one has to consider available options for your own drug pipeline as well as the position of others.

This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

- * Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- * Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- * Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- * Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- * Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any antibody drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

Table of Contents

1	Executive Summary	3
2	About Cancer Highlights	4
3	Methodologies	6
4	Table of Contents	8
4.1	List of Figures	20
4.2	List of Tables	20
5	Introduction	30
5.1	Background to the Antibody Therapeutic Market	30
5.2	The Scope of this Report	30
5.3	Definitions	35
5.4	Abbreviations	35
6	Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment	36
6.1	Drug Repositioning in Oncology	36
6.2	Introduction to Antibody Therapeutic Targets in Oncology	37

6.2.1	Antigen Binding Targets	41	
6.2.2	Auxiliary Transport Protein Activity Targets	42	
6.2.3	B Cell Receptor Activity Targets	43	
6.2.4	Carboxypeptidase Activity Targets	44	
6.2.5	Catalytic Activity Targets	45	
6.2.6	Cell Adhesion Molecule Activity Targets	47	
6.2.7	Cell Adhesion Molecule Activity Targets	48	
6.2.8	Chaperone Activity Targets	63	
6.2.9	Chemokine Activity Targets	66	
6.2.10	Cofactor Binding Targets	68	
6.2.11	Complement Activity Targets	70	
6.2.12	Cysteine-Type Peptidase Activity Targets	74	
6.2.13	Cytokine Activity Targets	75	
6.2.14	Defense/immunity Protein Activity Targets	80	
6.2.15	DNA Topoisomerase Activity Targets	81	
6.2.16	Extracellular Ligand-Gated Ion Channel Activity Targets	83	
6.2.17	Extracellular Matrix Structural Constituent Targets	84	
6.2.18	G-protein Coupled Receptor Activity Targets	88	
6.2.19	Growth Factor Activity Targets	93	
6.2.20	Hormone Activity Targets	105	
6.2.21	Hydrolase Activity Targets	106	
6.2.22	Intracellular Ligand-Gated Ion Channel Activity Targets	108	
6.2.23	Isomerase Activity Targets	109	
6.2.24	Kinase Binding Targets	110	
6.2.25	Lipid Kinase Activity Targets	111	
6.2.26	Metallopeptidase Activity Targets	113	
6.2.27	MHC Class I Receptor Activity Targets	115	
6.2.28	Molecular Function Unknown Targets	116	
6.2.29	Oxidoreductase Activity Targets	133	
6.2.30	Peptidase Activity Targets	134	
6.2.31	Peptide Hormone Targets	136	
6.2.32	Protease Inhibitor Activity Targets	137	
6.2.33	Protease Inhibitor Activity Targets	138	
6.2.34	Protein Binding Targets	139	
6.2.35	Protein Serine/Threonine Kinase Activity Targets	141	
6.2.36	Receptor Activity Targets	143	
6.2.37	Receptor Binding Targets	195	
6.2.38	Receptor Signaling Complex Scaffold Activity Targets	204	
6.2.39	RNA-directed DNA Polymerase Activity Targets	207	
6.2.40	Serine-type Peptidase Activity Targets	208	
6.2.41	Structural Constituent of Cytoskeleton Targets	211	
6.2.42	T cell Receptor Activity Targets	212	
6.2.43	Transcription Factor Activity Targets	214	
6.2.44	Transcription Regulator Activity Targets	217	
6.2.45	Transmembrane Receptor Activity Targets	220	
6.2.46	Transmembrane Receptor Protein Tyrosine Kinase Activity Targets	226	
6.2.47	Transporter Activity Targets	252	
6.2.48	Unclassified Targets	256	
6.3	The Cancer Genome Project and Antibody Therapeutic Targets in Oncology	257	
6.3.1	Antibody Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer	257	
6.4	Structure-based Drug Design in Antibody Therapeutics is Stimulated by Available Structure Data on Biological Targets	261	
6.5	Target-Target Interactions among Identified Antibody Therapeutics Targets in Oncology	265	
6.6	The Drug-Target Interactome	271	
6.7	Protein Expression Levels of Identified Antibody Therapeutic Targets in Oncology	276	
6.8	Pathway Analysis of Cancer Antibody Therapeutic Targets	281	
7	The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Antibody Therapeutic Pipeline?	320	
7.1	Terminated Drug Target Profiles of Cancer Antibody Drugs	325	
7.2	Pre-Registration to being Marketed: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology	330	
7.3	Phase III Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology	332	
7.4	Phase II Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology	334	
7.5	Phase I Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology	339	
7.6	Preclinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology	344	
7.7	Development Profiles of All Antibody Drugs in Oncology	351	
7.8	The Competition Through Close Mechanistic Approximation of Antibody Cancer Therapeutics	375	
8	Selecting Cancer Indications for Antibody Therapeutics	384	
8.1	Acute Lymphocytic Leukemia	387	
8.2	Acute Myelogenous Leukemia	389	
8.3	Basal Cell Cancer	391	
8.4	B-cell Lymphoma	392	
8.5	Biliary Cancer	394	
8.6	Bladder Cancer	395	
8.7	Bone Cancer	397	
8.8	Brain Cancer	398	
8.9	Breast Cancer	400	
8.10	Cancer (general)	404	
8.11	Cancer Diagnosis	406	

8.12	Cancer Fatigue	408	
8.13	Carcinoid Tumor	408	
8.14	Cervical Cancer	409	
8.15	Chemotherapy-induced Anemia	410	
8.16	Chemotherapy-induced Bone Marrow Injury (general)	410	410
8.17	Chemotherapy-induced Injury (general)	411	
8.18	Chemotherapy-induced Thrombocytopenia	411	411
8.19	Chronic Lymphocytic Leukemia	412	
8.20	Chronic Myelogenous Leukemia	415	
8.21	CNS Cancer	416	
8.22	Colorectal Cancer	417	
8.23	Endometrial Cancer	421	
8.24	Ewing's Sarcoma	422	
8.25	Fallopian Tube Cancer	423	
8.26	Gastrointestinal Cancer (general)	424	
8.27	Gastrointestinal Stomach Cancer	426	
8.28	Gastrointestinal Stromal Cancer	428	
8.29	Genitourinary Cancer	429	
8.30	Hairy Cell Leukemia	430	
8.31	Head and Neck Cancer	431	
8.32	Hematological Cancer (general)	433	
8.33	Hodgkin's Lymphoma	434	
8.34	Leiomyo Sarcoma	436	
8.35	Leukemia (general)	437	
8.36	Liver Cancer	438	
8.37	Lung Cancer (general)	440	
8.38	Lymphoma (general)	442	
8.39	Melanoma	443	
8.40	Merkel Cell Carcinoma	446	
8.41	Mesothelioma	447	
8.42	Myelodysplastic Syndrome	448	
8.43	Myeloma	449	
8.44	Nasopharyngeal Cancer	451	
8.45	Neuroblastoma	451	
8.46	Neuroectodermal Sarcoma	452	
8.47	Neuroendocrine Cancer (general)	453	
8.48	non-Hodgkin's Lymphoma	454	
8.49	Non-Small Cell Lung Cancer	458	
8.50	Oesophageal Cancer	461	
8.51	Osteo Sarcoma	463	
8.52	Ovarian Cancer	464	
8.53	Pancreatic Cancer	468	
8.54	Peritoneal Cancer	471	
8.55	Prostate Cancer	473	
8.56	Renal Cancer	476	
8.57	Rhabdomyo Sarcoma	478	
8.58	Sarcoma (general)	479	
8.59	Skin Cancer (general)	480	
8.60	Small Cell Lung Cancer	481	
8.61	Soft Tissue Sarcoma	484	
8.62	Solid Tumor	485	
8.63	Squamous Cell Cancer	486	
8.64	Synovial Sarcoma	487	
8.65	T-cell Lymphoma	488	
8.66	Testicular Cancer	489	
8.67	Thyroid Cancer	490	
8.68	Unspecified Cancer Indication	492	
8.69	Vaccine Adjunct	499	
9	Portfolio Planning: Competitive Benchmarking of Antibody Cancer Therapeutic Pipeline by Investigator		500
9.1	A&G Pharmaceutical	502	
9.2	Abiogen	505	
9.3	Ablynx	510	
9.4	AC Immune	513	
9.5	Access	516	
9.6	Actinium Pharmaceuticals	520	
9.7	Active Biotech	524	
9.8	Adherex	527	
9.9	Affibody	530	
9.10	Affimed Therapeutics	534	
9.11	Affitech	538	
9.12	AGY Therapeutics	542	
9.13	Aida Pharmaceuticals	545	
9.14	Alder Biopharmaceuticals	549	
9.15	Alethia Biotherapeutics	553	
9.16	Alexion	556	
9.17	Algeta	560	
9.18	Amgen	564	

9.19	Antisoma	575	
9.20	Aphios	579	
9.21	Arana Therapeutics	583	
9.22	Arca biopharma	586	
9.23	Astellas	589	
9.24	AstraZeneca	593	
9.25	Attenuon	604	
9.26	AVEO	607	
9.27	Bayer	611	
9.28	Berkeley Lab	615	
9.29	Biocon	618	
9.30	Biogen Idec	621	
9.31	BioInvent	631	
9.32	Biolex	634	
9.33	BioLineRx	638	
9.34	Biosceptre	641	
9.35	Biotechnol	644	
9.36	Boehringer Ingelheim	649	
9.37	Bristol-Myers Squibb	652	
9.38	BTG	664	
9.39	Cancer Innovations	668	
9.40	Cancer Research Technology	671	
9.41	Celldex Therapeutics	681	
9.42	Celtic Pharma	685	
9.43	Center of Molecular Immunology	689	
9.44	CG Therapeutics	695	
9.45	Circadian Technologies	698	
9.46	CuraGen	701	
9.47	CureTech	704	
9.48	Curis	707	
9.49	CytImmune Sciences	710	
9.50	Daiichi Sankyo	713	
9.51	Dendreon	717	
9.52	Dompe	720	
9.53	Dyax	723	
9.54	Eisai	727	
9.55	Elan	731	
9.56	Eli Lilly	734	
9.57	Epitomics	751	
9.58	EUSA Pharma	756	
9.59	Facet Biotech	759	
9.60	Faron Pharmaceuticals	765	
9.61	Favrille	768	
9.62	FibroGen	772	
9.63	Five Prime Therapeutics	775	
9.64	Fusion Antibodies	778	
9.65	Galaxy Biotech	781	
9.66	GammaCan	784	
9.67	Ganymed Pharmaceuticals	788	
9.68	Gene Techno Science	792	
9.69	Genentech	795	
9.70	Genmab	803	
9.71	GenPat77	816	
9.72	Genzyme	819	
9.73	GlaxoSmithKline	823	
9.74	Gliknik	828	
9.75	Glycotope	834	
9.76	Green Cross	841	
9.77	GTC Biotherapeutics	846	
9.78	Hoffmann-La Roche	850	
9.79	Human Genome Sciences	878	
9.80	IDM Pharma	884	
9.81	ImClone Systems	889	
9.82	ImmunoCellular Therapeutics	894	
9.83	ImmunoGen	898	
9.84	Immunomedics	907	
9.85	Innate Pharma	924	
9.86	InNexus Biotechnology	928	
9.87	Intracel	936	
9.88	ISA Pharmaceuticals	940	
9.89	ISU ABXIS	944	
9.90	Johnson & Johnson	949	
9.91	Kaketsuken	956	
9.92	KaloBios	959	
9.93	Kirin Pharma	962	
9.94	Kissei	966	
9.95	Kyowa Hakko Kirin	970	

9.96	LFB Biotechnologies	974
9.97	MacroGenics	977
9.98	MAT Biopharma	982
9.99	Medarex	986
9.100	MediGene	991
9.101	MedImmune	995
9.102	Menarini	999
9.103	Merck & Co	1002
9.104	Merck KGaA	1008
9.105	Merrimack	1015
9.106	Micromet	1018
9.107	MorphoSys	1030
9.108	Neovacs	1033
9.109	Neuren	1037
9.110	NKT Therapeutics	1040
9.111	Non-industrial Sources	1043
9.112	Northwest Biotherapeutics	1048
9.113	Novartis	1051
9.114	OncoMed	1059
9.115	Onyvax	1062
9.116	Oxford BioMedica	1065
9.117	Paladin Labs	1068
9.118	Panacea	1073
9.119	PanGenetics	1077
9.120	Patrys	1081
9.121	Pepscan Therapeutics	1085
9.122	Peregrine Pharmaceuticals	1090
9.123	Pfizer	1095
9.124	Philogen	1105
9.125	Pierre Fabre	1108
9.126	Prima Biomed	1114
9.127	ProCell Therapeutics	1117
9.128	Prochon Biotech	1120
9.129	Progenics Pharmaceuticals	1123
9.130	Protherics	1126
9.131	Ramot	1129
9.132	Recepta biopharma	1132
9.133	Receptor BioLogix	1135
9.134	Regeneron	1139
9.135	Sanofi-Aventis	1144
9.136	Scancell	1147
9.137	Seattle Genetics	1150
9.138	Sirtex Medical	1158
9.139	Sunol Molecular	1162
9.140	SuppreMol	1165
9.141	Switch Pharma	1168
9.142	Symphogen	1171
9.143	SynerGene Therapeutics	1176
9.144	Takeda	1179
9.145	Targa Therapeutics	1182
9.146	TeGenero	1187
9.147	Teva	1190
9.148	Therapure Biopharma	1193
9.149	ThromboGenics	1196
9.150	Titan Pharmaceuticals	1199
9.151	Tolerx	1204
9.152	Tracon Pharmaceuticals	1207
9.153	Trillium Therapeutics	1210
9.154	Trion Pharma	1213
9.155	Trubion	1218
9.156	UCB	1221
9.157	United Therapeutics	1225
9.158	Vaccinex	1228
9.159	VasGene Therapeutics	1233
9.160	Viragen	1236
9.161	Viventia Biotech	1239
9.162	Willex	1242
9.163	Xencor	1245
9.164	Xerion	1257
9.165	Xoma	1262
9.166	Y's Therapeutics	1266
10	Disclaimer	1269
11	Drug Index	1270
12	Company Index	1282

List of Figures

Figure 1: Visualization of Target-Target Interactions among Antibody Drug Targets in Oncology 270

Figure 2: The Drug-Protein Interactome of Antibody Drugs –Large Clusters	272
Figure 3: The Drug-Protein Interactome of Antibody Drugs – Small Clusters	273
Figure 4: Head-to-Head Targeting Interactome of Antibody Drugs – Large Clusters	274
Figure 5: Head-to-Head Targeting Interactome of Antibody Drugs – Small Clusters	275

List of Tables

Table 1: Head to Head Competition among Apoptotic Drugs in Oncology	31
Table 2: Overall Breakdown of the Included Antibody Pipeline by Cancer Indication and Stage of Development	31
Table 3: Overview of Drug Target Profile Themes	37
Table 4: Terminally Ceased Therapeutic Antibody Targets in Oncology	38
Table 5: Drug Targets of Antibody Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census	258
Table 6: Identity of Antibody Drug Targets with Available Biological Structures	261
Table 7: Number of Target-Target Interactions among Antibody Drug Targets in Oncology	265
Table 8: Antibody Drug Targets with Available Protein Expression Profiles	276
Table 9: Pathway Summary	281
Table 10: Drug Targets without any Identified Assigned Pathways	281
Table 11: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology	284
Table 12: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology	299
Table 13: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology	318
Table 14: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness	320
Table 15: Top Competitive Antibody Target Profiles in Oncology	321
Table 16: Terminated Drug Target Strategies of Antibody Drugs in Oncology	325
Table 17 New and Unique Antibody Target Strategies in Cancer Currently in Pre-Registration to Marketed	330
Table 18: The Competition Through Close Mechanistic Approximation Between Pre-registration to Marketed Antibody Drugs in Oncology	331
Table 19: New and Unique Antibody Target Strategies in Cancer Currently in Phase III Clinical Development	332
Table 20: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Oncology	333
Table 21: New and Unique Antibody Target Strategies in Cancer Currently in Phase II Clinical Development	334
Table 22: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Oncology	336
Table 23 New and Unique Antibody Target Strategies in Cancer Currently in Phase I Clinical Development	339
Table 24: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Oncology	342
Table 25: New and Unique Antibody Target Strategies in Oncology Currently in Preclinical Development	344
Table 26: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Oncology	348
Table 27: The Progression, Maturity and Competitive Comparison of Antibody Drug Target Profiles in Cancer Drug Development	351
Table 28: The Competition Through Close Mechanistic Approximation Among All Antibody Drugs in Oncology	375
Table 29: Competitive Summary of Antibody Drugs by Cancer Indication	384
Table 30: Drug Target Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia	387
Table 31: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs	388
Table 32: Drug Target Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia	389
Table 33: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs	390
Table 34: Drug Target Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer	391
Table 35: Drug Target Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma	392
Table 36: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs	393
Table 37: Drug Target Profiles of Antibody Drugs for the Treatment of Biliary Cancer	394
Table 38: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs	394
Table 39: Drug Target Profiles of Antibody Drugs for the Treatment of Bladder Cancer	395
Table 40: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs	396
Table 41: Drug Target Profiles of Antibody Drugs for the Treatment of Bone Cancer	397
Table 42: Drug Target Profiles of Antibody Drugs for the Treatment of Brain Cancer	398
Table 43: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs	399
Table 44: Drug Target Profiles of Antibody Drugs for the Treatment of Breast Cancer	400
Table 45: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs	402
Table 46: Drug Target Profiles of Antibody Drugs for the Treatment of Cancer (general)	404
Table 47: The Competition through Close Mechanistic Approximation between Cancer (general)	404
Table 48: Drug Target Profiles of Antibody Drugs for Cancer Diagnosis	406
Table 49: The Competition through Close Mechanistic Approximation between Cancer Diagnosis Drugs	407
Table 50: Drug Target Profiles of Antibody Drugs for the Treatment of Cancer Fatigue	408
Table 51: Drug Target Profiles of Antibody Drugs for the Treatment of Carcinoid Tumor	408
Table 52: Drug Target Profiles of Antibody Drugs for the Treatment of Cervical Cancer	409
Table 53: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs	409
Table 54: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Anemia	410
Table 55: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Bone Marrow Injury (general)	410
Table 56: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Injury (general)	411
Table 57: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Thrombocytopenia	411
Table 58: Drug Target Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia	412
Table 59: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs	413
Table 60: Drug Target Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia	415
Table 61: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia	415
Table 62: Drug Target Profiles of Antibody Drugs for the Treatment of CNS Cancer	416
Table 63: Drug Target Profiles of Antibody Drugs for the Treatment of Colorectal Cancer	417
Table 64: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs	419
Table 65: Drug Target Profiles of Antibody Drugs for the Treatment of Endometrial Cancer	421
Table 66: Drug Target Profiles of Antibody Drugs for the Treatment of Ewing's Sarcoma	422
Table 67: The Competition through Close Mechanistic Approximation between Ewing's Sarcoma Drugs	422
Table 68: Drug Target Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer	423
Table 69: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general)	424
Table 70: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs	425

Table 71: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer	426	
Table 72: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs	427	
Table 73: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer	428	
Table 74: Drug Target Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer	429	
Table 75: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs	429	
Table 76: Drug Target Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia	430	
Table 77: Drug Target Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer	431	
Table 78: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs	432	
Table 79: Drug Target Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general)	433	
Table 80: Drug Target Profiles of Antibody Drugs for the Treatment of Hodgkin's Lymphoma	434	
Table 81: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs	435	
Table 82: Drug Target Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma	436	
Table 83: Drug Target Profiles of Antibody Drugs for the Treatment of Leukemia (general)	437	
Table 84: Drug Target Profiles of Antibody Drugs for the Treatment of Liver Cancer	438	
Table 85: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs	439	
Table 86: Drug Target Profiles of Antibody Drugs for the Treatment of Lung Cancer (general)	440	
Table 87: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs	441	
Table 88: Drug Target Profiles of Antibody Drugs for the Treatment of Lymphoma (general)	442	
Table 89: Drug Target Profiles of Antibody Drugs for the Treatment of Melanoma	443	
Table 90: The Competition through Close Mechanistic Approximation between Melanoma Drugs	444	
Table 91: Drug Target Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma	446	
Table 92: Drug Target Profiles of Antibody Drugs for the Treatment of Mesothelioma	447	
Table 93: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs	447	
Table 94: Drug Target Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome	448	
Table 95: Drug Target Profiles of Antibody Drugs for the Treatment of Myeloma	449	
Table 96: The Competition through Close Mechanistic Approximation between Myeloma Drugs	450	
Table 97: Drug Target Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer	451	
Table 98: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroblastoma	451	
Table 99: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma	452	
Table 100: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general)	453	
Table 101: Drug Target Profiles of Antibody Drugs for the Treatment of non-Hodgkin's Lymphoma	454	
Table 102: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs	456	
Table 103: Drug Target Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer	458	
Table 104: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs	460	
Table 105: Drug Target Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer	461	
Table 106: The Competition through Close Mechanistic Approximation between Oesophageal Cancer	462	
Table 107: Drug Target Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma	463	
Table 108: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs	463	
Table 109: Drug Target Profiles of Antibody Drugs for the Treatment of Ovarian Cancer	464	
Table 110: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs	467	
Table 111: Drug Target Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer	468	
Table 112: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs	470	
Table 113: Drug Target Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer	471	
Table 114: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs	472	
Table 115: Drug Target Profiles of Antibody Drugs for the Treatment of Prostate Cancer	473	
Table 116: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs	475	
Table 117: Drug Target Profiles of Antibody Drugs for the Treatment of Renal Cancer	476	
Table 118: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs	477	
Table 119: Drug Target Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma	478	
Table 120: The Competition through Close Mechanistic Approximation between rhabdomyo sarcoma Drugs	478	
Table 121: Drug Target Profiles of Antibody Drugs for the Treatment of Sarcoma (general)	479	
Table 122: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs	479	
Table 123: Drug Target Profiles of Antibody Drugs for the Treatment of Skin Cancer (general)	480	
Table 124: Drug Target Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer	481	
Table 125: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs	483	
Table 126: Drug Target Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma	484	
Table 127: Drug Target Profiles of Antibody Drugs for the Treatment of Solid Tumor	485	
Table 128: Drug Target Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer	486	
Table 129: Drug Target Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma	487	
Table 130: Drug Target Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma	488	
Table 131: Drug Target Profiles of Antibody Drugs for the Treatment of Testicular Cancer	489	
Table 132: Drug Target Profiles of Antibody Drugs for the Treatment of Thyroid Cancer	490	
Table 133: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs	490	
Table 134: Drug Target Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Indication	492	
Table 135: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs	496	
Table 136: Drug Target Profiles of Antibody Drugs as Vaccine Adjunct	499	
Table 137: A&G Pharmaceutical's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	502	
Table 138: Abiogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	505	
Table 139: Ablynx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	510	
Table 140: AC Immune's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	513	
Table 141: Access' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	516	
Table 142: Actinium Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	520	
Table 143: Active Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	524	
Table 144: Adherex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	527	
Table 145: Affibody's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	530	
Table 146: Affimed Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	534	
Table 147: Affitech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	538	

Table 148: AGY Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	542
Table 149: Aida Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	545
Table 150: Alder Biopharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	549
Table 151: Alethia Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	553
Table 152: Alexion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	556
Table 153: Algeta's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	560
Table 154: Amgen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	564
Table 155: Antisoma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	575
Table 156: Aphios' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	579
Table 157: Arana Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	583
Table 158: Arca biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	586
Table 159: Astellas' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	589
Table 160: AstraZeneca's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	593
Table 161: Attenuon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	604
Table 162: AVEO's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	607
Table 163: Bayer's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	611
Table 164: Berkeley Lab's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	615
Table 165: Biocon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	618
Table 166: Biogen Idec's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	621
Table 167: BioInvent's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	631
Table 168: Bioclex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	634
Table 169: BioLineRx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	638
Table 170: Biosceptre's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	641
Table 171: Biotecol's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	644
Table 172: Boehringer Ingelheim's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	649
Table 173: Bristol-Myers Squibb's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	652
Table 174: BTG's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	664
Table 175: Cancer Innovations' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	668
Table 176: Cancer Research Technology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	671
Table 177: Celldex Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	681
Table 178: Celtic Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	685
Table 179: Center of Molecular Immunology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	689
Table 180: CG Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	695
Table 181: Circadian Technologies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	698
Table 182: CuraGen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	701
Table 183: CureTech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	704
Table 184: Curis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	707
Table 185: CytImmune Sciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	710
Table 186: Daiichi Sankyo's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	713
Table 187: Dendreon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	717
Table 188: Dompe's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	720
Table 189: Dyax's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	723
Table 190: Eisai's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	727
Table 191: Elan's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	731
Table 192: Eli Lilly's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	734
Table 193: Epitomics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	751
Table 194: EUSA Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	756
Table 195: Facet Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	759
Table 196: Faron Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	765
Table 197: Favrilles' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	768
Table 198: FibroGen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	772
Table 199: Five Prime Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	775
Table 200: Fusion Antibodies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	778
Table 201: Galaxy Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	781
Table 202: GammaCan's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	784
Table 203: Ganymed Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	788
Table 204: Gene Techno Science's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	792
Table 205: Genentech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	795
Table 206: Genmab's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	803
Table 207: GenPat77's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	816
Table 208: Genzyme's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	819
Table 209: GlaxoSmithKline's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	823
Table 210: Gliknik's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	828
Table 211: Glycotope's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	834
Table 212: Green Cross' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	841
Table 213: GTC Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	846
Table 214: Hoffmann-La Roche's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	850
Table 215: Human Genome Sciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	878
Table 216: IDM Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	884
Table 217: ImClone Systems' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	889
Table 218: ImmunoCellular Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	894
Table 219: ImmunoGen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	898
Table 220: Immunomedics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	907
Table 221: Innate Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	924
Table 222: InNexus Biotechnology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	928
Table 223: Intracel's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	936
Table 224: ISA Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	940

Table 225: ISU ABXIS's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	944
Table 226: Johnson & Johnson's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	949
Table 227: Kaketsuken's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	956
Table 228: KaloBios' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	959
Table 229: Kirin Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	962
Table 230: Kissei's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	966
Table 231: Kyowa Hakko Kirin's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	970
Table 232: LFB Biotechnologies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	974
Table 233: MacroGenics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	977
Table 234: MAT Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	982
Table 235: Medarex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	986
Table 236: MediGene's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	991
Table 237: MedImmune's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	995
Table 238: Menarini's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	999
Table 239: Merck & Co's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1002
Table 240: Merck KGaA's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1008
Table 241: Merrimack's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1015
Table 242: Micromet's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1018
Table 243: MorphoSys' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1030
Table 244: Neovacs' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1033
Table 245: Neuren's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1037
Table 246: NKT Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1040
Table 247: Non-industrial source's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1043
Table 248: Northwest Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1048
Table 249: Novartis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1051
Table 250: OncoMed's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1059
Table 251: Onyvax's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1062
Table 252: Oxford BioMedica's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1065
Table 253: Paladin Labs' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1068
Table 254: Panacea's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1073
Table 255: PanGenetics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1077
Table 256: Patrys' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1081
Table 257: Pepscan Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1085
Table 258: Peregrine Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1090
Table 259: Pfizer's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1095
Table 260: Philogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1105
Table 261: Pierre Fabre's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1108
Table 262: Prima Biomed's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1114
Table 263: ProCell Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out	1117

Ordering

Order Online - <http://www.bioseeker.com/market-research-report/antibody-drug-target-atlas-in-oncology-where-to-commercialize-in-a-crowded-market-place.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioSeeker Group
 Björnåsvägen 21
 11419 STOCKHOLM
 SWEDEN

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit <http://www.bioseeker.com/market-research-report/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?**

Web Address: <http://www.bioseeker.com/market-research-report/antibody-drug-target-atlas-in-oncology-where-to-commercialize-in-a-crowded-market-place.html>

Format: PDF

Price: 2450 EUR (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 EUR.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number: _____

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by credit card:

American Express

Master Card

Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

Pay by check:

Please post the check, accompanied by this form, to:

BioMarket Group

Björnnäsvägen 21

11419 STOCKHOLM

SWEDEN

Pay by wire transfer: Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioSeeker Group you are agreeing to our Terms and Conditions at

<http://www.bioseeker.com/market-research-report/biomarket-group-full-terms-and-conditions/>

Please fax this form to: +46-8-56849191